The Bolstering Research And Innovation Now (BRAIN) Act seeks to advance medical breakthroughs in brain tumor treatment and enhance the adequacy and awareness of specialized cancer and brain tumor care. Congress finds that despite over a million people living with brain tumors and pediatric brain tumors being a leading cause of cancer-related death in young people, treatment advancements and survival rates for malignant brain tumors have remained stagnant for decades. The bill aims to address this by strengthening research and treatment development while improving access to and awareness of specialized care. To bolster research, the Act mandates the establishment of a searchable website for NIH-funded brain tumor biospecimen collections , requiring reporting from entities maintaining such collections. It also creates a Glioblastoma Therapeutics Network , authorizing $50 million for fiscal years 2026-2030 to evaluate therapeutic agents from pre-clinical to early-phase clinical trials. Furthermore, it establishes a Brain Tumor Related Cellular Immunotherapy Team Science Award , allocating $10 million for the same period to support multi-institutional research and clinical trials for CAR-T and other immunotherapies. The bill also focuses on improving awareness and patient access through a national public awareness campaign on cancer clinical trials and biomarker testing. This campaign will provide culturally and linguistically competent materials and public service announcements, targeting high-risk populations and rural communities. Additionally, it authorizes grants for demonstration projects to test outreach and education strategies for patients, families, and healthcare professionals regarding clinical trials and biomarker testing, with $10 million authorized for fiscal years 2026-2030. Finally, the Act authorizes pilot programs to develop and evaluate approaches for monitoring and caring for adult and pediatric brain tumor survivors throughout their lifespan, including models for post-treatment care transition and coordination, with $5 million authorized annually for fiscal years 2026-2030. It also directs the FDA to issue guidance within one year to minimize the exclusion of brain tumor patients from clinical trials for other indications.